Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Gene Therapy

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...

Gene Therapy

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...

Satellite Stem Cells and Muscular Dystrophy

Satellite Stem Cells and Muscular Dystrophy

Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Simulations of allosteric motions in the zinc sensor CzrA.

Journal of the American Chemical Society·2011

Same author

[Platelet parameters and platelet Toll-like receptor 4 (TLR4) expression in patients with sepsis, and the effect of a joint treatment-plan integrating traditional Chinese and western medicine: a clinical study].

Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue·2011

Same author

A novel kernel Fisher discriminant analysis: constructing informative kernel by decision tree ensemble for metabolomics data analysis.

Analytica chimica acta·2011

Same author

Anterior debridement and reconstruction via thoracoscopy-assisted mini-open approach for the treatment of thoracic spinal tuberculosis: minimum 5-year follow-up.

European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society·2011

Same author

[A family-based association study of FXYD6 gene polymorphisms and schizophrenia].

Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics·2011

Same author

Prenatal diagnosis of penoscrotal transposition with 2- and 3-dimensional ultrasonography.

Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine·2011

Search research articles

Related Experiment Video

Updated: Jun 16, 2026

CRISPR/Cas9 Technology in Restoring Dystrophin Expression in iPSC-Derived Muscle Progenitors

CRISPR/Cas9 Technology in Restoring Dystrophin Expression in iPSC-Derived Muscle Progenitors

Published on: September 14, 2019

AAV-directed muscular dystrophy gene therapy.

Ying Tang¹, James Cummins, Johnny Huard

¹University of Pittsburgh, Department of Orthopaedic Surgery, Pittsburgh, PA 15261, USA.

Expert Opinion on Biological Therapy

|February 6, 2010

Summary

Recombinant adeno-associated viral (rAAV) vectors enable long-term gene transfer for genetic muscle diseases. Optimizing rAAV strategies and administration methods can overcome challenges in gene therapy for muscular dystrophies.

More Related Videos

Quantification of Adeno-Associated Viral Genomes in Purified Vector Samples by Digital Droplet Polymerase Chain Reaction

Quantification of Adeno-Associated Viral Genomes in Purified Vector Samples by Digital Droplet Polymerase Chain Reaction

Published on: October 11, 2024

Related Experiment Videos

Last Updated: Jun 16, 2026

CRISPR/Cas9 Technology in Restoring Dystrophin Expression in iPSC-Derived Muscle Progenitors

CRISPR/Cas9 Technology in Restoring Dystrophin Expression in iPSC-Derived Muscle Progenitors

Published on: September 14, 2019

Quantification of Adeno-Associated Viral Genomes in Purified Vector Samples by Digital Droplet Polymerase Chain Reaction

Quantification of Adeno-Associated Viral Genomes in Purified Vector Samples by Digital Droplet Polymerase Chain Reaction

Published on: October 11, 2024

Area of Science:

Biomedical research
Gene therapy
Musculoskeletal disorders

Background:

Muscle-directed gene therapy utilizes recombinant adeno-associated viral (rAAV) vectors for sustained therapeutic gene transfer in genetic muscle diseases.
Recent advancements focus on rAAV-vector-mediated gene transfer for treating muscular dystrophies (MD).

Purpose of the Study:

To review recent progress in rAAV-vector-mediated muscle-directed gene transfer for MD treatment.
To compare different administration methods, promoters, and animal models to guide clinical trial strategies.

Main Methods:

Review of literature from the past 2-3 years on rAAV gene therapy for muscular dystrophies.
Analysis of strategies including mini-dystrophin replacement, exon skipping, muscle regeneration enhancement, and inflammation reduction.

Main Results:

rAAV gene therapy can restore muscle histopathology and function through mini-dystrophin replacement and exon-skipping.
Enhancing muscle regeneration and reducing inflammation are key to optimizing therapeutic efficacy.
Different administration routes, promoters, and animal models present unique advantages and disadvantages.

Conclusions:

Systemic rAAV gene delivery has successfully restored muscle function and histopathology.
Combining gene replacement with adjuvant therapies may improve muscle regeneration and reduce necrosis.
Optimizing rAAV vectors and administration is crucial for overcoming challenges in large animal and human trials, particularly regarding gene transfer efficiency and immune response.